464 related articles for article (PubMed ID: 25979856)
1. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
Liu C; Guo Q; Lu M; Li Y
Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
[TBL] [Abstract][Full Text] [Related]
2. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
3. Hydrogen Sulfide Up-Regulates the Expression of ATP-Binding Cassette Transporter A1 via Promoting Nuclear Translocation of PPARα.
Li D; Xiong Q; Peng J; Hu B; Li W; Zhu Y; Shen X
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136542
[TBL] [Abstract][Full Text] [Related]
4. Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E-deficient mice.
Shi ST; Li YF; Guo YQ; Wang ZH
J Cardiovasc Pharmacol; 2014 Nov; 64(5):407-11. PubMed ID: 24979391
[TBL] [Abstract][Full Text] [Related]
5. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
8. Red clover extract ameliorates dyslipidemia in streptozotocin-induced diabetic C57BL/6 mice by activating hepatic PPARα.
Qiu L; Ye H; Chen L; Hong Y; Zhong F; Zhang T
Phytother Res; 2012 Jun; 26(6):860-4. PubMed ID: 22084061
[TBL] [Abstract][Full Text] [Related]
9. The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression.
Kim HJ; Moon JH; Kim HM; Yun MR; Jeon BH; Lee B; Kang ES; Lee HC; Cha BS
Metabolism; 2014 Jan; 63(1):112-9. PubMed ID: 24139096
[TBL] [Abstract][Full Text] [Related]
10. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
12. Effects of Danhong injection on dyslipidemia and cholesterol metabolism in high-fat diets fed rats.
Du H; Li C; Wang Z; He Y; Wang Y; Zhou H; Wan H; Yang J
J Ethnopharmacol; 2021 Jun; 274():114058. PubMed ID: 33766756
[TBL] [Abstract][Full Text] [Related]
13. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
15. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism.
Shin SK; Ha TY; McGregor RA; Choi MS
Mol Nutr Food Res; 2011 Dec; 55(12):1829-40. PubMed ID: 22058071
[TBL] [Abstract][Full Text] [Related]
16. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
17. Daming capsule, a hypolipidaemic drug, lowers blood lipids by activating the AMPK signalling pathway.
Bian Y; Li X; Li X; Ju J; Liang H; Hu X; Dong L; Wang N; Li J; Zhang Y; Yang B
Biomed Pharmacother; 2019 Sep; 117():109176. PubMed ID: 31387185
[TBL] [Abstract][Full Text] [Related]
18. The expression and role of peroxisome proliferator-activated receptor α in atherosclerosis.
Gao W; Xu W; Li H
Mol Med Rep; 2013 Mar; 7(3):862-8. PubMed ID: 23337913
[TBL] [Abstract][Full Text] [Related]
19. Role of peroxisome proliferator-activated receptor α in atherosclerosis.
Cao H; Wen G; Li H
Mol Med Rep; 2014 May; 9(5):1755-60. PubMed ID: 24604149
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
